Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
73.28
-0.54 (-0.74%)
At close: Jun 12, 2026, 4:00 PM EDT
73.75
+0.47 (0.65%)
After-hours: Jun 12, 2026, 6:39 PM EDT
Ionis Pharmaceuticals Employees
Ionis Pharmaceuticals had 1,402 employees as of December 31, 2025. The number of employees increased by 333 or 31.15% compared to the previous year.
Employees
1,402
Change (1Y)
333
Growth (1Y)
31.15%
Revenue / Employee
$754,772
Profits / Employee
-$233,222
Market Cap
12.11B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,402 | 333 | 31.15% |
| Dec 31, 2024 | 1,069 | 142 | 15.32% |
| Dec 31, 2023 | 927 | 131 | 16.46% |
| Dec 31, 2022 | 796 | 136 | 20.61% |
| Dec 31, 2021 | 660 | -97 | -12.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 3,088 |
| Jazz Pharmaceuticals | 2,890 |
| Axsome Therapeutics | 1,220 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| BridgeBio Pharma | 839 |
IONS News
- 2 days ago - Ionis Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 4 days ago - Ionis Pharmaceuticals appoints Hantson to Board of Directors - TheFly
- 4 days ago - Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors - Business Wire
- 8 days ago - Ionis Pharmaceuticals Transcript: AGM 2026 - Transcripts
- 8 days ago - Ionis Pharmaceuticals Slides: FY 2026 - Filings
- 8 days ago - Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses - Business Wire
- 15 days ago - Ionis partner GSK reports B-Well 1, B-Well 2 trials meet primary endpoint - TheFly
- 15 days ago - Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B - Business Wire